US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

UpStream Bio Inc.

6.48

-0.0700-1.07%

Post-market: 6.560.0800+1.23%19:37 EDT

Volume:515.61K

Turnover:3.36M

Market Cap:354.92M

PE:-2.25

High:6.98

Open:6.62

Low:6.41

Close:6.55

52wk High:33.68

52wk Low:5.85

Shares:54.77M

Float Shares:46.68M

Volume Ratio:1.00

T/O Rate:1.10%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.8758

EPS(LYR):-2.6636

ROE:-46.05%

ROA:-30.28%

PB:1.31

PE(LYR):-2.43

Loading ...

Overview Company News Filings

Upstream Bio Q1 EPS $(0.75) Beats $(0.77) Estimate, Sales $1.034M Beat $442.000K Estimate

Benzinga Earnings

Upstream Bio Q1 FY26 net loss widens 48.83% to $40.59 million

Upstream Bio Inc Q1 Collaboration Revenue USD 1.034 Million

THOMSON REUTERS

Press Release: Upstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights

Upstream Bio Inc expected to post a loss of 77 cents a share - Earnings Preview

Upstream Bio to present Phase 2 VIBRANT verekitug data at ATS 2026 conference

Upstream Bio announces annual shareholder meeting via webcast

Upstream Bio publishes corporate presentation outlining verekitug Phase 3 plans in asthma, CRSwNP

Analysts Offer Insights on Healthcare Companies: Upstream Bio, Inc. (UPB) and Pfizer (PFE)

Upstream Bio Cut to In-Line From Outperform by Evercore ISI Group

Top Premarket Decliners

MT Newswires Live

Evercore ISI Downgrades Upstream Bio to In Line From Outperform, Adjusts PT to $15 From $40

MT Newswires Live

Upstream Bio Launches $150 Million At-The-Market Program

Upstream Bio announces $150 million at-the-market equity distribution agreement with Leerink Partners

Upstream Bio Inc - Enters Sales Agreement With Leerink Partners Llc for Common Stock Offering of up to $150 Mln - SEC Filing

THOMSON REUTERS

Upstream Bio Initiated at Buy: Verekitug’s Quarterly Dosing Strategy Positions It for Potential Best-in-Class Efficacy vs. TSLP Competitors

Verekitug’s Differentiated Long-Interval Dosing and Late-Stage Pipeline Position It as a Potential Respiratory Blockbuster

Buy Rating Backed by VALIANT Phase 2 Asthma Data and Differentiated, Infrequent-Dosing Profile for Verekitug

Upstream Bio Q4 net loss widens on higher R&D costs

Upstream Bio FY2025 net loss widens 128.4% to $143 million; research and development expenses rise 117.3% to $137 million

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/stock/UPB/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"UPB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"UPB\",,,,,undefined,":{"symbol":"UPB","market":"US","secType":"STK","nameCN":"UpStream Bio Inc.","latestPrice":6.48,"timestamp":1788379200000,"preClose":6.55,"halted":0,"volume":515608,"hourTrading":{"tag":"盘后","latestPrice":6.56,"preClose":6.48,"latestTime":"19:37 EDT","volume":12881,"amount":83412.1211616,"timestamp":1788392239606,"change":0.08,"changeRate":0.012346,"amplitude":0.067901},"delay":0,"changeRate":-0.010687022900763267,"floatShares":46680775,"shares":54771041,"eps":-2.875781,"marketStatus":"Post-Mkt","change":-0.07,"latestTime":"09-02 19:55:51 EDT","open":6.62,"high":6.98,"low":6.41,"amount":3361114.3392376,"amplitude":0.087023,"askPrice":7.76,"askSize":100,"bidPrice":5.59,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.875781,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1788393600000},"marketStatusCode":4,"adr":0,"listingDate":1728619200000,"exchange":"NASDAQ","adjPreClose":6.55,"postHourTrading":{"tag":"盘后","latestPrice":6.56,"preClose":6.48,"latestTime":"19:37 EDT","volume":12881,"amount":83412.1211616,"timestamp":1788392239606,"change":0.08,"changeRate":0.012346,"amplitude":0.067901},"volumeRatio":0.997322,"impliedVol":0.7908,"impliedVolPercentile":0.4087},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"UPB\",,,,,undefined,":{"symbol":"UPB","floatShares":46680775,"roa":"-30.28%","roe":"-46.05%","lyrEps":-2.663615,"volumeRatio":0.997322,"shares":54771041,"dividePrice":0,"high":6.98,"amplitude":0.087023,"preClose":6.55,"low":6.41,"week52Low":5.85,"pbRate":"1.31","psRate":"112.39","week52High":33.68,"institutionHeld":0,"latestPrice":6.48,"eps":-2.875781,"divideRate":0,"volume":515608,"delay":0,"ttmEps":-2.875781,"open":6.62,"prevYearClose":27.15,"prevWeekClose":6.69,"prevMonthClose":6.62,"prevQuarterClose":6.92,"fiveDayClose":7.13,"twentyDayClose":6.74,"sixtyDayClose":6.45},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/UPB\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-11","symbol":"UPB","fiscalQuarterEnding":"2026/06","expectedEps":-0.78,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786420800000,"reportTimeType":"pre","actualEps":-0.73},{"market":"US","date":"2026-05-13","symbol":"UPB","fiscalQuarterEnding":"2026/03","expectedEps":-0.8,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778644800000,"reportTimeType":"pre","actualEps":-0.75},{"market":"US","date":"2026-03-26","symbol":"UPB","fiscalQuarterEnding":"2025/12","expectedEps":-0.73,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1774497600000,"reportTimeType":"pre","actualEps":-0.79},{"market":"US","date":"2025-05-06","symbol":"UPB","fiscalQuarterEnding":"2025/03","expectedEps":-0.49,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1746504000000,"reportTimeType":"pre","actualEps":-0.51},{"market":"US","date":"2025-03-12","symbol":"UPB","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1741752000000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"UPB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"UPB\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1111,"buy":0.6667,"hold":0.2222,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":9,"updateTime":1781323200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/UPB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"UPB","date":"2026-09-01","current":-2.277642,"percent":0.955414,"low":-36.237602,"twenty":-12.795845,"median":-7.964314,"eighty":-3.503893,"high":-2.055104,"avg":-9.486896,"sd":7.00523,"marketCap":362584291},"quantilePoints":[{"date":"2024-10-11","current":-21.547111,"twenty":-21.096119,"median":-20.419631,"eighty":-19.743142,"marketCap":872808815},{"date":"2024-10-18","current":-29.91246,"twenty":-29.856691,"median":-29.151973,"eighty":-22.814588,"marketCap":1211664002},{"date":"2024-10-25","current":-33.154958,"twenty":-33.128498,"median":-29.931472,"eighty":-28.137991,"marketCap":1343007876},{"date":"2024-10-31","current":-32.943274,"twenty":-33.154958,"median":-32.429578,"eighty":-29.151973,"marketCap":1334433205},{"date":"2024-11-08","current":-35.748083,"twenty":-33.28726,"median":-32.943274,"eighty":-29.633615,"marketCap":1448047598},{"date":"2024-11-15","current":-26.036965,"twenty":-33.27403,"median":-32.40745,"eighty":-26.47861,"marketCap":1390295829},{"date":"2024-11-22","current":-17.866537,"twenty":-33.154958,"median":-29.91246,"eighty":-25.555171,"marketCap":954019497},{"date":"2024-11-29","current":-21.951751,"twenty":-33.154958,"median":-29.151973,"eighty":-21.870823,"marketCap":1172157663},{"date":"2024-12-06","current":-22.082237,"twenty":-33.144374,"median":-26.689395,"eighty":-21.903572,"marketCap":1179125222},{"date":"2024-12-13","current":-20.486294,"twenty":-33.088806,"median":-26.036965,"eighty":-21.589777,"marketCap":1093906626},{"date":"2024-12-20","current":-16.672089,"twenty":-32.969734,"median":-24.742143,"eighty":-20.201232,"marketCap":890239542},{"date":"2024-12-27","current":-19.517686,"twenty":-32.858694,"median":-23.382078,"eighty":-19.472518,"marketCap":1042185906},{"date":"2025-01-03","current":-16.36093,"twenty":-32.784605,"median":-22.553994,"eighty":-19.153329,"marketCap":873624596},{"date":"2025-01-10","current":-16.250519,"twenty":-32.617811,"median":-22.077219,"eighty":-18.486847,"marketCap":867728970},{"date":"2025-01-17","current":-10.92067,"twenty":-31.635576,"median":-21.951751,"eighty":-17.320504,"marketCap":583131018},{"date":"2025-01-24","current":-10.810259,"twenty":-29.950484,"median":-21.600443,"eighty":-16.501454,"marketCap":577235392},{"date":"2025-01-31","current":-11.041119,"twenty":-29.91246,"median":-20.852659,"eighty":-16.230444,"marketCap":589562611},{"date":"2025-02-07","current":-8.561886,"twenty":-29.633615,"median":-19.703378,"eighty":-11.472726,"marketCap":457179006},{"date":"2025-02-14","current":-7.3574,"twenty":-29.151973,"median":-19.472518,"eighty":-10.92067,"marketCap":392863085},{"date":"2025-02-21","current":-8.260764,"twenty":-28.137991,"median":-19.276941,"eighty":-10.810259,"marketCap":441100026},{"date":"2025-02-28","current":-7.839194,"twenty":-27.097043,"median":-19.030874,"eighty":-9.965112,"marketCap":418589453},{"date":"2025-03-07","current":-8.451474,"twenty":-26.562924,"median":-18.338294,"eighty":-8.834903,"marketCap":451283380},{"date":"2025-03-14","current":-7.737899,"twenty":-26.318012,"median":-17.866537,"eighty":-8.491624,"marketCap":485986508},{"date":"2025-03-21","current":-6.875286,"twenty":-26.085144,"median":-16.857781,"eighty":-8.411325,"marketCap":431809204},{"date":"2025-03-28","current":-5.816236,"twenty":-26.012875,"median":-16.36093,"eighty":-8.168077,"marketCap":365294494},{"date":"2025-04-04","current":-5.380659,"twenty":-25.645507,"median":-16.240482,"eighty":-7.936302,"marketCap":337937638},{"date":"2025-04-11","current":-5.466066,"twenty":-24.254326,"median":-13.751211,"eighty":-7.734483,"marketCap":343301728},{"date":"2025-04-17","current":-7.191293,"twenty":-23.886958,"median":-11.472726,"eighty":-7.5722,"marketCap":451656335},{"date":"2025-04-25","current":-7.652492,"twenty":-23.286723,"median":-11.041119,"eighty":-7.514132,"marketCap":480622419},{"date":"2025-05-02","current":-7.693506,"twenty":-22.857123,"median":-10.850408,"eighty":-7.502769,"marketCap":483198327},{"date":"2025-05-09","current":-6.005612,"twenty":-22.499792,"median":-10.810259,"eighty":-7.378434,"marketCap":475536334},{"date":"2025-05-16","current":-5.964849,"twenty":-22.162536,"median":-10.288315,"eighty":-7.189481,"marketCap":472308712},{"date":"2025-05-23","current":-6.324914,"twenty":-22.076215,"median":-9.921951,"eighty":-6.77963,"marketCap":500819374},{"date":"2025-05-30","current":-6.352089,"twenty":-22.02402,"median":-9.013568,"eighty":-6.524152,"marketCap":502971123},{"date":"2025-06-06","current":-7.357554,"twenty":-21.951751,"median":-8.668839,"eighty":-6.524152,"marketCap":582585803},{"date":"2025-06-13","current":-7.853492,"twenty":-21.855392,"median":-8.531773,"eighty":-6.551855,"marketCap":621855206},{"date":"2025-06-20","current":-7.228474,"twenty":-21.688772,"median":-8.441437,"eighty":-6.588317,"marketCap":572364999},{"date":"2025-06-27","current":-7.432284,"twenty":-21.589777,"median":-8.421362,"eighty":-6.683973,"marketCap":588503110},{"date":"2025-07-03","current":-7.60892,"twenty":-21.547111,"median":-8.293047,"eighty":-6.875286,"marketCap":602489473},{"date":"2025-07-11","current":-8.043715,"twenty":-21.219023,"median":-8.229183,"eighty":-7.004282,"marketCap":636917443},{"date":"2025-07-18","current":-7.500221,"twenty":-20.486294,"median":-8.00983,"eighty":-7.116503,"marketCap":593882481},{"date":"2025-07-25","current":-9.06956,"twenty":-20.325696,"median":-7.964314,"eighty":-7.165671,"marketCap":718145935},{"date":"2025-08-01","current":-10.401121,"twenty":-19.703378,"median":-8.043715,"eighty":-7.186764,"marketCap":823581592},{"date":"2025-08-08","current":-8.173881,"twenty":-19.517686,"median":-8.19076,"eighty":-7.191293,"marketCap":853925323},{"date":"2025-08-15","current":-9.608438,"twenty":-19.472518,"median":-8.256445,"eighty":-7.228474,"marketCap":1003793530},{"date":"2025-08-22","current":-9.154334,"twenty":-19.472518,"median":-8.332111,"eighty":-7.228474,"marketCap":956353234},{"date":"2025-08-29","current":-8.648626,"twenty":-19.29215,"median":-8.429698,"eighty":-7.242061,"marketCap":903521996},{"date":"2025-09-05","current":-10.155428,"twenty":-19.267816,"median":-8.442215,"eighty":-7.274671,"marketCap":1060937523},{"date":"2025-09-12","current":-9.247219,"twenty":-19.117195,"median":-8.531282,"eighty":-7.282823,"marketCap":966056931},{"date":"2025-09-19","current":-8.911801,"twenty":-19.040911,"median":-8.561886,"eighty":-7.298422,"marketCap":931015804},{"date":"2025-09-26","current":-8.416414,"twenty":-18.814066,"median":-8.561394,"eighty":-7.303028,"marketCap":879262754},{"date":"2025-10-03","current":-9.592957,"twenty":-18.486847,"median":-8.591998,"eighty":-7.324944,"marketCap":1002176247},{"date":"2025-10-10","current":-10.212191,"twenty":-18.290115,"median":-8.630565,"eighty":-7.351996,"marketCap":1066867560},{"date":"2025-10-17","current":-11.4971,"twenty":-18.113457,"median":-8.648626,"eighty":-7.357523,"marketCap":1201102033},{"date":"2025-10-24","current":-10.903668,"twenty":-17.908694,"median":-8.694854,"eighty":-7.362988,"marketCap":1139106192},{"date":"2025-10-31","current":-13.298037,"twenty":-17.320504,"median":-8.903157,"eighty":-7.366819,"marketCap":1389245933},{"date":"2025-11-07","current":-10.460565,"twenty":-17.071577,"median":-8.919541,"eighty":-7.375835,"marketCap":1278553063},{"date":"2025-11-14","current":-10.319087,"twenty":-16.746366,"median":-8.953083,"eighty":-7.3842,"marketCap":1261260713},{"date":"2025-11-21","current":-11.035322,"twenty":-16.535581,"median":-9.042102,"eighty":-7.390371,"marketCap":1348803231},{"date":"2025-11-28","current":-12.644639,"twenty":-16.41714,"median":-9.068084,"eighty":-7.395598,"marketCap":1545503702},{"date":"2025-12-05","current":-12.264416,"twenty":-16.306728,"median":-9.154334,"eighty":-7.402392,"marketCap":1499030514},{"date":"2025-12-12","current":-12.145044,"twenty":-16.258549,"median":-9.253501,"eighty":-7.413262,"marketCap":1484440094},{"date":"2025-12-19","current":-13.201711,"twenty":-16.238474,"median":-9.412348,"eighty":-7.419454,"marketCap":1613592327},{"date":"2025-12-26","current":-13.38298,"twenty":-16.206354,"median":-9.577476,"eighty":-7.422171,"marketCap":1635748149},{"date":"2026-01-02","current":-12.003565,"twenty":-15.686418,"median":-9.608438,"eighty":-7.426849,"marketCap":1467147745},{"date":"2026-01-09","current":-12.175992,"twenty":-13.691713,"median":-9.623919,"eighty":-7.437719,"marketCap":1488222796},{"date":"2026-01-16","current":-13.661516,"twenty":-14.223893,"median":-9.706483,"eighty":-7.459459,"marketCap":1669792461},{"date":"2026-01-23","current":-14.055003,"twenty":-14.055003,"median":-9.763246,"eighty":-7.459459,"marketCap":1717886807},{"date":"2026-01-30","current":-13.679201,"twenty":-14.055003,"median":-9.837934,"eighty":-7.487886,"marketCap":1671954005},{"date":"2026-02-06","current":-11.495127,"twenty":-13.997527,"median":-9.967119,"eighty":-7.498759,"marketCap":1405003366},{"date":"2026-02-13","current":-5.659139,"twenty":-13.966579,"median":-10.045793,"eighty":-7.487886,"marketCap":691693964},{"date":"2026-02-20","current":-3.775707,"twenty":-13.794285,"median":-9.921951,"eighty":-7.430925,"marketCap":461489567},{"date":"2026-02-27","current":-3.49275,"twenty":-13.743121,"median":-9.768407,"eighty":-7.40375,"marketCap":426904868},{"date":"2026-03-06","current":-3.391062,"twenty":-13.712802,"median":-9.724309,"eighty":-7.375835,"marketCap":414475992},{"date":"2026-03-13","current":-4.171405,"twenty":-13.705728,"median":-9.63424,"eighty":-7.351996,"marketCap":509854106},{"date":"2026-03-20","current":-3.704968,"twenty":-13.684506,"median":-9.611018,"eighty":-7.282823,"marketCap":452843392},{"date":"2026-03-27","current":-3.71417,"twenty":-13.665053,"median":-9.577476,"eighty":-7.221038,"marketCap":532771662},{"date":"2026-04-02","current":-3.532065,"twenty":-13.632336,"median":-9.412348,"eighty":-7.146004,"marketCap":506650069},{"date":"2026-04-10","current":-3.953182,"twenty":-13.517385,"median":-9.253501,"eighty":-6.612231,"marketCap":567056254},{"date":"2026-04-17","current":-3.831779,"twenty":-13.45372,"median":-9.154334,"eighty":-6.50272,"marketCap":549641858},{"date":"2026-04-24","current":-3.642087,"twenty":-13.411276,"median":-9.068084,"eighty":-6.341219,"marketCap":522431865},{"date":"2026-05-01","current":-3.482746,"twenty":-13.38298,"median":-9.030487,"eighty":-6.247466,"marketCap":499575471},{"date":"2026-05-08","current":-3.408766,"twenty":-13.356783,"median":-8.950503,"eighty":-6.042298,"marketCap":488963574},{"date":"2026-05-15","current":-3.051413,"twenty":-13.336336,"median":-8.911801,"eighty":-5.873814,"marketCap":478351676},{"date":"2026-05-22","current":-2.936855,"twenty":-13.312561,"median":-8.871357,"eighty":-5.82388,"marketCap":460393081},{"date":"2026-05-29","current":-2.888254,"twenty":-13.287802,"median":-8.694854,"eighty":-5.684399,"marketCap":452774283},{"date":"2026-06-05","current":-2.579294,"twenty":-13.258302,"median":-8.648626,"eighty":-5.496812,"marketCap":404340495},{"date":"2026-06-12","current":-2.214791,"twenty":-13.222933,"median":-8.630565,"eighty":-5.216676,"marketCap":347199510},{"date":"2026-06-18","current":-2.134948,"twenty":-13.191984,"median":-8.604831,"eighty":-4.257618,"marketCap":334682913},{"date":"2026-06-26","current":-2.207848,"twenty":-13.129203,"median":-8.561886,"eighty":-4.092265,"marketCap":346111110},{"date":"2026-07-02","current":-2.527222,"twenty":-13.033705,"median":-8.501661,"eighty":-3.922831,"marketCap":396177498},{"date":"2026-07-10","current":-2.71121,"twenty":-12.989493,"median":-8.446844,"eighty":-3.831779,"marketCap":425020090},{"date":"2026-07-17","current":-2.509865,"twenty":-12.97623,"median":-8.429698,"eighty":-3.775707,"marketCap":393456498},{"date":"2026-07-24","current":-2.221734,"twenty":-12.962966,"median":-8.408673,"eighty":-3.733139,"marketCap":348287910},{"date":"2026-07-31","current":-2.280749,"twenty":-12.929663,"median":-8.332111,"eighty":-3.686663,"marketCap":357539308},{"date":"2026-08-07","current":-2.384893,"twenty":-12.91308,"median":-8.260764,"eighty":-3.654227,"marketCap":373865303},{"date":"2026-08-14","current":-2.418325,"twenty":-12.836708,"median":-8.229183,"eighty":-3.58648,"marketCap":378467893},{"date":"2026-08-21","current":-2.397327,"twenty":-12.813742,"median":-8.043715,"eighty":-3.543056,"marketCap":375181630},{"date":"2026-08-28","current":-2.376328,"twenty":-12.809108,"median":-7.975124,"eighty":-3.522202,"marketCap":371895368},{"date":"2026-09-01","current":-2.316833,"twenty":-12.795845,"median":-7.964314,"eighty":-3.503893,"marketCap":362584291}],"updateTime":1788350625933},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"UPB\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2635789332","title":"Upstream Bio Q1 EPS $(0.75) Beats $(0.77) Estimate, Sales $1.034M Beat $442.000K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2635789332","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635789332?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:12","pubTimestamp":1778670748,"startTime":"0","endTime":"0","summary":"Upstream Bio (NASDAQ:UPB) reported quarterly losses of $(0.75) per share which beat the analyst consensus estimate of $(0.77) by 2.6 percent. This is a 47.06 percent decrease over losses of $(0.51) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52517838/upstream-bio-q1-eps-0-75-beats-0-77-estimate-sales-1-034m-beat-442-000k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UPB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635786917","title":"Upstream Bio Q1 FY26 net loss widens 48.83% to $40.59 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635786917","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635786917?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:04","pubTimestamp":1778670242,"startTime":"0","endTime":"0","summary":"Upstream Bio posted a net loss of USD 40.59 million for first-quarter 2026, widening from a loss of USD 27.27 million a year earlier.Research and development expense climbed to USD 36.57 million from USD 25.8 million, while general and administrative costs rose to USD 8.08 million from USD 6.78 million.Collaboration revenue increased to USD 1.03 million from USD 566,000, while cash, cash equivalents and short-term investments totaled USD 294.6 million as of March 31, 2026.More than 400 participants enrolled in Phase 2 VENTURE trial in COPD; further enrollment will be capped, with placebo-controlled efficacy data now expected in second half of 2027.End-of-Phase 2 meetings with FDA planned for mid-2026, with Phase 3 initiations in severe asthma and CRSwNP expected in Q1 2027.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL5Zksyn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UPB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635878502","title":"Upstream Bio Inc Q1 Collaboration Revenue USD 1.034 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635878502","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635878502?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:00","pubTimestamp":1778670003,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nPLX79E5EF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","UPB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635785056","title":"Press Release: Upstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2635785056","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635785056?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:00","pubTimestamp":1778670000,"startTime":"0","endTime":"0","summary":"-- Company rapidly advancing Phase 3 programs designed to deliver best-in-class efficacy with convenient quarterly dosing in severe asthma and CRSwNP --. -- End-of-Phase 2 meetings with FDA planned for mid-2026; Phase 3 initiations in both indications expected in Q1 2027 --. \"We continue to make strong progress advancing our clinical programs in severe asthma and CRSwNP to position verekitug as a uniquely differentiated treatment option for these diseases,\" said Rand Sutherland, MD, Chief Executive Officer of Upstream Bio. \"We are working diligently to deliver best-in-class efficacy with convenient quarterly at-home dosing, a profile that we believe will advance the standard of care for patients and maximize the potential commercial value of verekitug. We are continuing to prepare for our End-of-Phase 2 meetings with the FDA, which we expect to occur in mid-2026, and we remain on track to initiate Phase 3 dosing in both severe asthma and CRSwNP in the first quarter of 2027.\"","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSLP","BK4161","UPB","ATS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632161284","title":"Upstream Bio Inc  expected to post a loss of 77 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2632161284","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632161284?lang=en_us&edition=fundamental","pubTime":"2026-05-01 20:37","pubTimestamp":1777639039,"startTime":"0","endTime":"0","summary":"Upstream Bio Inc  expected to post a loss of77cents a share - Earnings Preview Upstream Bio Inc UPB.OQ UPB.O is expected to  show a fall in quarterly revenue when it reports  results on May 4 (estimat","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nL8N41E0W7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","UPB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628086112","title":"Upstream Bio to present Phase 2 VIBRANT verekitug data at ATS 2026 conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2628086112","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628086112?lang=en_us&edition=fundamental","pubTime":"2026-04-17 19:01","pubTimestamp":1776423712,"startTime":"0","endTime":"0","summary":"Upstream Bio scheduled new Phase 2 VIBRANT trial data for verekitug in chronic rhinosinusitis with nasal polyps for presentation at ATS 2026 on May 18, 2026.Posters will cover clinical effects in patients with comorbid asthma, signaling potential positioning in a higher-need subgroup.Separate analyses will outline verekitug impact on nasal and blood biomarkers, supporting its profile as a TSLP receptor antagonist in development.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nNDL75k7jD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","SG9999014039.USD","LU2210150020.SGD","IE00BKPKM429.USD","LU2210149790.SGD","SG9999014013.SGD","BK4139","LU0314104364.USD","IE00B3QW5Z07.USD","BK4585","BK4588","SG9999014021.USD","LU2095319765.USD","SG9999014005.SGD","IE00BN0W2W23.USD","BK4112","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","NDAQ","UPB","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628246760","title":"Upstream Bio announces annual shareholder meeting via webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2628246760","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628246760?lang=en_us&edition=fundamental","pubTime":"2026-04-17 04:06","pubTimestamp":1776369995,"startTime":"0","endTime":"0","summary":"Upstream Bio scheduled 2026 annual shareholder meeting for June 9, 2026 via virtual webcast.Shareholders set to vote on election of two Class II directors, with H. Edward Fleming Jr. nominated for a new term running to 2029.Ballot also includes Liam Ratcliffe as Class II director nominee for a term running to 2029.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Upstream Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 16, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nNDL91qSKQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UPB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625672448","title":"Upstream Bio publishes corporate presentation outlining verekitug Phase 3 plans in asthma, CRSwNP","url":"https://stock-news.laohu8.com/highlight/detail?id=2625672448","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625672448?lang=en_us&edition=fundamental","pubTime":"2026-04-06 22:17","pubTimestamp":1775485064,"startTime":"0","endTime":"0","summary":"Upstream Bio outlined plans to initiate Phase 3 trials of verekitug in severe asthma and chronic rhinosinusitis with nasal polyps in Q1 2027.Program update showed Phase 2 trials completed in severe asthma and chronic rhinosinusitis with nasal polyps.Severe asthma Phase 2 VALIANT trial reported a 56% reduction in annualized asthma exacerbation rate with 100 mg dosed every 12 weeks.Chronic rhinosinusitis with nasal polyps Phase 2 VIBRANT trial met primary endpoint with nasal polyp score reduction of 1.8.Upstream Bio projected existing capital to fund planned operations through 2027.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Upstream Bio Inc. published the original content used to generate this news brief on April 06, 2026, and is so","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nNDLkHyGF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","UPB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625162188","title":"Analysts Offer Insights on Healthcare Companies: Upstream Bio, Inc. (UPB) and Pfizer (PFE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2625162188","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625162188?lang=en_us&edition=fundamental","pubTime":"2026-04-06 10:30","pubTimestamp":1775442608,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Upstream Bio, Inc. (UPB) and Pfizer (PFE). Upstrea...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-upstream-bio-inc-upb-and-pfizer-pfe-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-upstream-bio-inc-upb-and-pfizer-pfe-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0225771236.USD","SG9999001176.USD","SG9999002224.SGD","SG9999003800.SGD","LU0122379950.USD","LU1023059063.AUD","BK4534","SG9999002232.USD","SGXZ57979304.SGD","UPB","BK4533","BK4007","LU1894683264.USD","BK4588","IE00BLSP4239.USD","IE00BBT3K403.USD","LU0170899867.USD","SG9999011175.SGD","LU0058720904.USD","BK4139","SG9999013999.USD","LU0225284248.USD","IE00B19Z3B42.SGD","BK4581","BK4568","BK4585","BK4137","LU1066053197.SGD","LU0029874061.USD","LU0985481810.HKD","IE00B19Z3581.USD","LABU","LU0306806265.USD","XBI","LU1883839398.USD","BK4592","IE0002270589.USD","BK4550","LU0234572021.USD","LU0289739699.SGD","LU0868494617.USD","LU1066051498.USD","IE000M9KFDE8.USD","LU0321505868.SGD","LU0321505439.SGD","LU0456855351.SGD","SG9999001176.SGD","IE00BLSP4452.SGD","PFE","LU1057294990.SGD","LU0306807586.USD","BK4599","LU0128526141.USD","LU1894683348.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622873526","title":"Upstream Bio Cut to In-Line From Outperform by Evercore ISI Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2622873526","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622873526?lang=en_us&edition=fundamental","pubTime":"2026-03-27 22:57","pubTimestamp":1774623420,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/UPB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 27, 2026 10:57 ET (14:57 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","UPB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622263978","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2622263978","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622263978?lang=en_us&edition=fundamental","pubTime":"2026-03-27 19:51","pubTimestamp":1774612307,"startTime":"0","endTime":"0","summary":"Urban-gro  shares were down 8% in Friday premarket activity, extending the previous session's loss.Upstream Bio  stock was down 6.4%, a day after the company posted a higher Q4 net loss from a year earlier, while Evercore ISI also downgraded the company to in-line from outperform and lowered its price target to $15 from $40.Two Harbors Investment  stock was down 2.6%, after the company said it has signed a deal to be acquired by CrossCountry Mortgage for $10.80 per share in cash, terminating its previously announced Dec. 17 merger agreement with UWM Holdings .Wix.com  shares were 2.1% lower, after JPMorgan downgraded the company to underweight from neutral and lowered its price target to $91 from $114.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4116","BK4585","UPB","BK4229","BK4110","BK4152","UWMC","BK4588","UGRO","WIX","BK4548","TWO","BK4195","BK4139"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2622828153","title":"Evercore ISI Downgrades Upstream Bio to In Line From Outperform, Adjusts PT to $15 From $40","url":"https://stock-news.laohu8.com/highlight/detail?id=2622828153","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622828153?lang=en_us&edition=fundamental","pubTime":"2026-03-27 18:48","pubTimestamp":1774608513,"startTime":"0","endTime":"0","summary":"Upstream Bio (UPB) has an average rating of buy and mean price target of $44.17, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks a","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["UPB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622689451","title":"Upstream Bio Launches $150 Million At-The-Market Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2622689451","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622689451?lang=en_us&edition=fundamental","pubTime":"2026-03-27 05:30","pubTimestamp":1774560616,"startTime":"0","endTime":"0","summary":"Upstream Bio, Inc. ( ($UPB) ) has issued an update. On March 26, 2026, Upstream Bio, Inc. entered into a sales agreement with Leerink Partners LLC ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/upstream-bio-launches-150-million-at-the-market-program?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/upstream-bio-launches-150-million-at-the-market-program?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","UPB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622193891","title":"Upstream Bio announces $150 million at-the-market equity distribution agreement with Leerink Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2622193891","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622193891?lang=en_us&edition=fundamental","pubTime":"2026-03-27 05:10","pubTimestamp":1774559409,"startTime":"0","endTime":"0","summary":"Upstream Bio entered into an at-the-market equity distribution agreement with Leerink Partners as sales agent for sales of common stock.The program allows sales of up to USD 150.0 million of shares from time to time through or to the agent.Leerink Partners is entitled to a commission of up to 3% of gross proceeds on shares sold under the agreement.Sales may be made on Nasdaq or other existing trading markets for the common stock.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Upstream Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 26, 2026, and is solely responsible for th","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL2MPsh8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4207","BK4139","MNSH","UPB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622919638","title":"Upstream Bio Inc - Enters Sales Agreement With Leerink Partners Llc for Common Stock Offering of up to $150 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2622919638","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622919638?lang=en_us&edition=fundamental","pubTime":"2026-03-27 05:06","pubTimestamp":1774559217,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nFWN40E0ZM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["UPB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622898676","title":"Upstream Bio Initiated at Buy: Verekitug’s Quarterly Dosing Strategy Positions It for Potential Best-in-Class Efficacy vs. TSLP Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2622898676","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622898676?lang=en_us&edition=fundamental","pubTime":"2026-03-27 01:45","pubTimestamp":1774547119,"startTime":"0","endTime":"0","summary":"William Blair analyst Matt Phipps has maintained their bullish stance on UPB stock, giving a Buy rating today. Matt Phipps has given his Buy rating...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/upstream-bio-initiated-at-buy-verekitugs-quarterly-dosing-strategy-positions-it-for-potential-best-in-class-efficacy-vs-tslp-competitors-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/upstream-bio-initiated-at-buy-verekitugs-quarterly-dosing-strategy-positions-it-for-potential-best-in-class-efficacy-vs-tslp-competitors-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","UPB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622867477","title":"Verekitug’s Differentiated Long-Interval Dosing and Late-Stage Pipeline Position It as a Potential Respiratory Blockbuster","url":"https://stock-news.laohu8.com/highlight/detail?id=2622867477","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622867477?lang=en_us&edition=fundamental","pubTime":"2026-03-27 00:45","pubTimestamp":1774543520,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Yaron Werber has maintained their bullish stance on UPB stock, giving a Buy rating today. Yaron Werber has given his Buy rating du...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/verekitugs-differentiated-long-interval-dosing-and-late-stage-pipeline-position-it-as-a-potential-respiratory-blockbuster-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/verekitugs-differentiated-long-interval-dosing-and-late-stage-pipeline-position-it-as-a-potential-respiratory-blockbuster-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SSI","UPB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622586254","title":"Buy Rating Backed by VALIANT Phase 2 Asthma Data and Differentiated, Infrequent-Dosing Profile for Verekitug","url":"https://stock-news.laohu8.com/highlight/detail?id=2622586254","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622586254?lang=en_us&edition=fundamental","pubTime":"2026-03-26 23:45","pubTimestamp":1774539917,"startTime":"0","endTime":"0","summary":"LifeSci Capital analyst Kate Dellorusso has maintained their bullish stance on UPB stock, giving a Buy rating on March 11. Kate Dellorusso has give...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-backed-by-valiant-phase-2-asthma-data-and-differentiated-infrequent-dosing-profile-for-verekitug-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-backed-by-valiant-phase-2-asthma-data-and-differentiated-infrequent-dosing-profile-for-verekitug-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","UPB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622785118","title":"Upstream Bio Q4 net loss widens on higher R&D costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2622785118","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622785118?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:07","pubTimestamp":1774523256,"startTime":"0","endTime":"0","summary":"Upstream Bio Q4 net loss widens on higher R&D costsOverviewUS biotech firm's Q4 collaboration revenue was modest, net loss widened due to higher R&D costsCompany expects cash of $341.5 mln to fund ope","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nL1N40E0DK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UPB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622851551","title":"Upstream Bio FY2025 net loss widens 128.4% to $143 million; research and development expenses rise 117.3% to $137 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622851551","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622851551?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:02","pubTimestamp":1774522954,"startTime":"0","endTime":"0","summary":"Upstream Bio published a press release reporting fourth-quarter and full-year 2025 financial results and outlining its Phase 3 development strategy for verekitug in severe asthma and chronic rhinosinusitis with nasal polyps.Cash, cash equivalents and short-term investments totaled USD 341.5 million as of Dec. 31, 2025, with the company expecting this to fund planned operations through 2027.Research and development expenses rose 84.46% to USD 40.2 million for the quarter, driven primarily by higher clinical and manufacturing expenses for verekitug programs.Net loss widened 99.86% to USD 42.5 million for the quarter.Management said it plans to initiate dosing in Phase 3 trials for verekitug in severe asthma and CRSwNP in Q1 2027, following positive Phase 2 results and planned FDA engagement later this year.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL8rp4hV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00BKPKM429.USD","UPB","IE00B64PRP62.GBP","BK4588","LU2095319765.USD","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","LU2210150020.SGD","BK4585","SG9999014021.USD","SG9999014013.SGD","IE00B3QW5Z07.USD","BK4112","IE00BGHQF748.EUR","SG9999014005.SGD","NDAQ","LU0314104364.USD","SG9999014039.USD","IE00BN0W2V16.EUR","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":67,"code":"91000000","status":"200"}]}}